Androgen Receptor‐Induced Lactoferrin Accelerates Prostate Tumorigenesis Through Modulating Ferroptosis
Advanced Science · 2026-07 · 13 (37)
DOI: 10.1002/advs.202520109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 07.04.2026. Verfasst von Can Liu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital/ The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South Univers…. Hauptthemen laut MEDLINE: Lactoferrin, Ferroptosis, Receptors, Androgen, Prostatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Ningbo Top Medical and Health Research Program, Ningbo Municipal Key Medical Discipline (Western Medicine) Development Project.
Abstract (Originalsprache)
Lactoferrin (LF), an innate immunity molecule, showed a strikingly high expression level in the human prostate compared to other tissues and organs, indicating a significant role in prostate physiology. Despite the tumor‐suppressive role of lactoferrin established in other malignancies, we reveal its paradoxical oncogenic function in prostate cancer through an androgen receptor (AR)‐LF‐ferroptosis axis. Utilizing Lf −/− TRAMP genetic mouse models, proteomics, TCGA‐PARD data, and single‐cell RNA‐seq, we demonstrate that AR directly binds the LF promoter, driving LF expression, which in turn upregulates ferritin (FTH1/FTL) expression and suppresses p53‐ALOX12‐mediated ferroptosis in prostate cancer. Crucially, Lf deficiency delayed tumor progression and intensified ferroptotic stress in the TRAMP mice, while iron supplementation accelerated carcinogenesis—effects rescued by Lf knockout. Mechanistically, lactoferrin shields prostate cancer cells from iron‐induced ferroptosis by maintaining iron‐redox homeostasis. Preclinical targeting of this axis suggested a potential therapeutic strategy, as suppressed tumor growth in prostate cancer xenograft was observed following LF knockdown coupled with ferroptosis induction (via IKE) and androgen receptor inhibition (via enzalutamide). This work defines lactoferrin as: (i) an AR‐regulated ferroptosis suppressor, (ii) a regulator of prostate cancer's “iron addiction,” and (iii) a candidate target for therapeutic exploitation of iron‐metabolic vulnerability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital/ The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
- Cancer Research Institute, Xiangya School of Basic Medical Science, Central South University, Changsha, Hunan, China.
- Ningbo Clinical Pathology Diagnosis Center, Ningbo, Zhejiang, China.
- Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Furong Laboratory, Changsha,…
- Shanxi Provincial Center For Upper Gastrointestinal Cancer Research and Clinical Translation, Laboratory of Clinical Research Center, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China.
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
ORCID-Profile: Jian Ma
Förderung
- National Natural Science Foundation of China
- Ningbo Top Medical and Health Research Program
- Ningbo Municipal Key Medical Discipline (Western Medicine) Development Project
- Fundamental Research Programs of Shanxi Province
- Science and technology innovation plan of Shanxi Higher Education Institutions-Young Academic Leaders
- China 111 Project
- China Postdoctoral Science Foundation
- Hunan Natural Sciences Foundation
Zitieren
APA
Liu, C., Peng, Q., Zhang, X., Li, Z., Wu, Y., Wen, Y., Zheng, R., Wu, S., Zhou, C., Hu, Z., Shu, L., Ma, X., Li, Q., Ma, Y., Ou, C., Zhao, M., Fan, S., Wei, L., & Ma, J. (2026). Androgen Receptor‐Induced Lactoferrin Accelerates Prostate Tumorigenesis Through Modulating Ferroptosis. Advanced Science, 13(37). https://doi.org/10.1002/advs.202520109
Vancouver
Liu C, Peng Q, Zhang X, Li Z, Wu Y, Wen Y, et al. Androgen Receptor‐Induced Lactoferrin Accelerates Prostate Tumorigenesis Through Modulating Ferroptosis. Advanced Science. 2026;13(37). doi:10.1002/advs.202520109
BibTeX
@article{Liu2026,
author = {Liu, Can and Peng, Qiu and Zhang, Xiaoyue and Li, Zhengshuo and Wu, Yangge and Wen, Yuqing and Zheng, Run and Wu, Shuanglong and Zhou, Chenfei and Hu, Zhengyu and Shu, Lanjun and Ma, Xinyi and Li, Qiuyang and Ma, Ya and Ou, Chunlin and Zhao, Ming and Fan, Songqing and Wei, Lingyu and Ma, Jian},
title = {Androgen Receptor‐Induced Lactoferrin Accelerates Prostate Tumorigenesis Through Modulating Ferroptosis},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {37},
doi = {10.1002/advs.202520109}
}
EUVIMED